Torrent
partners with Reliance Life to sell biosimilars in India
Ahmedabad-based
Torrent Pharmaceuticals Ltd today announced that the company has entered into
an exclusive licensing agreement with Reliance Life Sciences for marketing
three biosimilars in the Indian market.
In
an announcement made on Thursday, Torrent Pharmaceuticals informed that
Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences
and supplied to Torrent Pharma after obtaining all necessary regulatory
approvals. Torrent Pharma will be the only company to market these biosimilars
in India other than Reliance Life Sciences, a company statement said here.
As
per the terms of agreement, Reliance Life Sciences will manufacture these
products at its facility in Navi Mumbai and supply to Torrent Pharma for a
period of ten years.
Rituximab
and Cetuximab cater to the oncology segment and are used in the treatment of
various cancers like leukemia, lymphoma, colorectal, head and neck cancers.
Adalimumab is the most preferred therapy for the treatment of auto immune
disorders like rheumatoid arthritis, psoriasis and IBD.
"Torrent
Pharma forayed into the oncology and dermatology segments in 2011-12 with the
launch of exclusive divisions and has since gained a strong position in these
segments. The licensing agreement with Reliance Life Sciences is expected to
significantly boost its presence in these segments in the coming years,"
it said.
No comments:
Post a Comment